The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.
Jeeyun Lee
No relevant relationships to disclose
Do Hoon Lim
No relevant relationships to disclose
Sung Kim
No relevant relationships to disclose
Se Hoon Park
No relevant relationships to disclose
Joon Oh Park
No relevant relationships to disclose
Ho Yeong Lim
No relevant relationships to disclose
Seung Tae Kim
No relevant relationships to disclose
Kyoung-Mee Kim
No relevant relationships to disclose
Won Ki Kang
No relevant relationships to disclose